CASE STUDY: Positioning AccuPlace for Pandemic-Era Demand — AccuPlace’s COVID-19 Biotechnology Success

CASE STUDY / Positioning AccuPlace for Pandemic-Era Demand — AccuPlace’s COVID-19 Biotechnology Success

BACKGROUND

AccuPlace is a manufacturer of precision automation and adhesive component placement equipment serving the semiconductor, electronics and life sciences industries. The company develops highly specialized machinery used for precision adhesive placement, automated robotic assembly, label and film application, laboratory slide printing, and custom automation systems supporting advanced manufacturing environments where speed, consistency, and micron-level accuracy are critical. Applications range from adhesive labeling and component placement for products such as oven doors and electronics to advanced adhesive and material applications supporting manufacturers such as 3M.

During the COVID-19 pandemic, AccuPlace recognized an opportunity to expand the relevance of its automation capabilities within the biotechnology and pharmaceutical sectors as global manufacturers accelerated vaccine development, testing, and production. While the company already possessed technology applicable to diagnostic and life sciences manufacturing — including precision systems capable of supporting test kit production and highly controlled assembly processes — its marketing and outreach efforts had not yet been positioned to effectively communicate those capabilities to biotechnology decision-makers operating under heightened urgency. 

AccuPlace engaged Grozina to develop the communications, digital marketing, and targeted outreach strategy necessary to strengthen visibility among leading biotechnology and pharmaceutical organizations — including companies involved in COVID-19 vaccine development — while translating highly technical machinery into clearer, application-based messaging aligned with urgent real-world manufacturing needs. 

CHALLENGE

The competitive environment intensified significantly during the COVID-19 pandemic as vaccine manufacturers and biotechnology firms operated under compressed production timelines while being inundated with vendors competing for attention. Reaching organizations such as Johnson & Johnson, Pfizer, and Moderna required communications that could clearly connect highly technical machinery to specific manufacturing outcomes. At the same time, audience dynamics within STEM and life sciences industries were evolving. As biotechnology, diagnostics, and pharmaceutical organizations increasingly included more women across scientific research, laboratory operations, procurement, and leadership roles, communications needed to account for broader and more multidisciplinary decision-making audiences. Messaging was refined to move beyond purely technical specifications toward language focused on real-world outcomes, allowing sophisticated engineering capabilities to be more effectively understood across teams responsible for evaluating equipment purchases. The objective was not to simplify the engineering, but to allow sophisticated technical capabilities to better adapt to the realities of the buyer environment.

STRATEGIC APPROACH

• Decided to target the world’s largest vaccine manufacturers — including Johnson & Johnson, Pfizer, and Moderna — because these organizations represented the highest-value opportunities for adoption during vaccine development and production efforts. These companies became major U.S. vaccine developers during the pandemic.
• Decided to simplify technical messaging and translate machinery capabilities into application-based language because stakeholders often evaluated outcomes differently than engineers, and increasing representation of women across scientific procurement, and leadership roles influenced how communications were received within biotechnology and STEM environments. Messaging shifted beyond purely technical specifications toward usability, precision, reliability, and real-world outcomes — remaining as precise as the micron-level accuracy of the machines themselves while becoming better aligned with how purchasing decisions were made during compressed pandemic timelines. 
• Decided to strengthen digital visibility through SEO, paid media, email marketing, and social content because digital discovery became increasingly central to vendor evaluation during pandemic-related disruptions.

EXECUTION HIGHLIGHTS

• Rebuilt SEO infrastructure, website architecture, and technical content to better align with biotechnology, life sciences, pharmaceutical manufacturing, and industrial automation search behavior before broader stakeholder outreach began. Complex technical concepts were translated into accessible, search-optimized language through educational and thought leadership content including The History of the Barcode, An In-Depth Cost Analysis of Label Automation vs. Manual Labor, How AccuPlace Can Help You Meet Increased Consumer Demand and Changing Consumer Preferences, Why Automation Should Be Implemented in Your Labeling Production Process, Here’s Why You Should Consider AccuPlace’s Automation System for Your Adhesive Labeling Process, How AccuPlace Automation Systems Solved Challenges in Medical Device Manufacturing During COVID-19 Testing and Vaccine Development, and AccuPlace, A Global Leader in Accurate and Complex Automation in the Medical, Computer, Automotive and Mobile Industries, strengthening discoverability, technical clarity, and market credibility.
• Refined technical communications and positioning frameworks to better explain how AccuPlace machinery supported testing kits, manufacturing precision, pharmaceutical production environments, and heightened COVID-19-related manufacturing demands.
• Optimized Google Ads, website content, and digital engagement to strengthen visibility among biotechnology, pharmaceutical, and life sciences decision-makers before targeted stakeholder engagement.
• Created segmented email campaigns and personalized messaging tailored to biotechnology and pharmaceutical stakeholders, aligning communications with operational priorities and manufacturing needs.
• Developed targeted outreach strategies focused on leading vaccine manufacturers, including Johnson & Johnson, Pfizer, and Moderna, after digital visibility, technical positioning, and market readiness had been strengthened.
• Expanded social media and digital storytelling to reinforce visibility and credibility during a period of heightened digital competition and accelerated demand for medical manufacturing solutions.

RESULTS AND IMPACT

AccuPlace strengthened visibility within life sciences and biotechnology sectors during a period of unprecedented global demand. Website engagement increased by 38%, improving reach among more qualified and industry-relevant audiences.

Targeted outreach generated engagement from multiple global pharmaceutical and biotechnology organizations, including leading COVID-19 vaccine manufacturers. One vaccine manufacturer out of the main three targets (Johnson & Johnson, Pfizer, and Moderna) moved forward with equipment acquisition to support the production of test kits used in COVID-19 vaccine development, while broader outreach generated additional interest and demand from other pharmaceutical and life sciences companies exploring automation solutions.

Most importantly, AccuPlace established a stronger market position within biotechnology and pharmaceutical manufacturing by translating highly technical automation expertise into clearer, application-based communications aligned with urgent real-world industry needs.